// App-Quantinova.ai

271 : Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Researchers

Presenter

  • Giacomo Gotti

Principal Investigators

  • Kristen E. Stevenson

  • Brenton G. Mar

  • Barbara L Asselin

  • Uma Athale

  • Luis A. Clavell

  • Peter D. Cole

  • Lisa M. Gennarini

  • Justine M. Kahn

  • Kara M. Kelly

  • Caroline Laverdiere

  • Jean-Marie Leclerc

  • Bruno Michon

  • Marshall A. Schorin

  • Maria L. Sulis

  • Thai Hoa Tran

  • Jennifer J.G. Welch

  • Kimberly Stegmaier

  • Marian H. Harris

  • Lewis B. Silverman

  • Yana Pikman

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA

  • Blueprint Medicines, Cambridge, MA

  • Golisano Children's Hospital at URMC, University of Rochester Strong Memorial Hospital, Rochester, NY

  • McMaster Children's Hospital, Division of Pediatric Hematology/Oncology, Hamilton, Canada

  • Division of Pediatric Oncology, San Jorge Childrens Hospital, San Juan, PR, Puerto Rico

  • Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ.

  • The Children's Hospital at Montefiore, Bronx, NY

  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Hematology-Oncology Division, Charles Bruneau Cancer Center, Sainte-Justine University Hospital, University of Montreal, Montreal, QC, Canada

  • CHU Sainte-Justine, Montreal, CAN

  • Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada

  • Inova Fairfax Hospital for Children, Falls Church, VA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Centre Hospitalier Universitaire, Quebec, Canada

  • Division of Pediatric Hematology-Oncology, Hasbro Children's Hospital, Providence, RI

  • Boston Children's Hospital, Department of Cardiology, Boston, MA, USA

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • B-Raf proto-oncogene, serine/threonine kinase

  • Paired box 5

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 3-kinase regulatory subunit alpha

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Polycomb repressive complex 2

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • CREB-binding protein

  • Cyclin D3

  • Cyclin Dependent Kinase Inhibitor 2A

  • Retinoblastoma protein

  • Embryonic ectoderm development

  • Enhancer of zeste homolog 2

  • ETV6-RUNX1

  • Fms related tyrosine kinase 3

  • GTPase Nras

  • Janus kinase

  • Janus kinase 3

  • KRAS proto-oncogene, GTPase

  • Tumor protein p53

  • Neurofibromatosis type 1

Drug/Treatment

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved